Uncle Bud’s Health and Wellness to Expand New Premium Collection with Novel Products for Sleep, Memory, Pain, Immunity, Feminine Hygiene, and Sexual Wellness
April 11, 2024 10:52 ET
|
Pressure BioSciences, Inc.
PBIO’s UltraShear Platform Enables Development and Launch of Health & Wellness Products with Revolutionary Bioavailability, Onset, and Effectiveness
Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”
April 02, 2024 10:19 ET
|
Pressure BioSciences, Inc.
PBIO's Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection
Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing
February 15, 2024 10:52 ET
|
Pressure BioSciences, Inc.
PBIO's Relocation Delivers Substantially Increased Manufacturing Space, Improved Operating Efficiencies, and Cost Savings for Unencumbered Growth
Uncle Bud’s to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness
February 05, 2024 08:23 ET
|
Pressure BioSciences, Inc.
Pressure BioSciences February 5th Investor Call to Discuss Recent Uncle Buds Acquisition
Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds
February 01, 2024 08:59 ET
|
Pressure BioSciences, Inc.
Uncle Bud’s 2024 Revenue Expected to Increase 3-Fold to Approximately $5 Million, Fueled by UltraShear Processed Nanoemulsion Product Introductions
Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million Dollar Shipment in January
January 16, 2024 08:47 ET
|
Pressure BioSciences, Inc.
SOUTH EASTON, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling...
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2022 18:00 ET
|
ProPhase Labs, Inc.
Garden City, NY, July 21, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it has granted an inducement stock option...
Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference
September 26, 2019 09:29 ET
|
Pressure BioSciences, Inc.
Ten Presentations by Scientists from Seventeen Research Institutions Worldwide Highlight Novel Applications for PBI’s PCT Platform in Cancer Research and Diagnostics South Easton, MA,...
Pressure BioSciences Prepares for Growth, Adding Daniel J. Shea as Chief Financial Officer
September 17, 2019 10:33 ET
|
Pressure BioSciences, Inc.
Shea’s 30-Year Diverse Experience in Acquisitions, Capital Markets, SEC Reporting, and Leading Financial Organizations Bolsters PBI’s Strong Senior Management Team South Easton, MA, Sept. 17,...
Pressure BioSciences’ PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and for Potential Clinical Diagnostics
September 10, 2019 09:33 ET
|
Pressure BioSciences, Inc.
Two Prestigious Research Centers Report PBI’s PCT Platform Delivers Superior Results for Protein Biomarker Discovery Studies from Preserved Cancer Biopsy Tissue Samples SOUTH EASTON, MA,...